AADI:NSD-Aadi Bioscience Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 13.43

Change

+0.66 (+5.17)%

Market Cap

USD 0.27B

Volume

0.15M

Avg Analyst Target

USD 41.00 (+205.29%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AADI Stock Forecast & Price:
Based on the Aadi Bioscience Inc stock forecasts from 3 analysts, the average analyst target price for Aadi Bioscience Inc is USD 41.00 over the next 12 months. Aadi Bioscience Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aadi Bioscience Inc is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Aadi Bioscience Inc’s stock price was USD 13.43. Aadi Bioscience Inc’s stock price has changed by +12.67% over the past week, -18.90% over the past month and 0% over the last year.

About Aadi Bioscience Inc (AADI:NSD)

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi i ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+1.66 (+0.58%)

USD73.48B 29.71 20.69
REGN Regeneron Pharmaceuticals Inc

+1.16 (+0.19%)

USD65.40B 8.39 6.44
MRNA Moderna Inc

+5.59 (+3.73%)

USD59.64B 4.20 3.05
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+3.53 (+2.24%)

USD38.28B 2.86 1.54
SGEN Seagen Inc

-3.34 (-1.85%)

USD33.15B 55.02 -51.02
RPRX Royalty Pharma Plc

+0.41 (+0.96%)

USD28.81B 29.89 16.23
GMAB Genmab AS

+0.51 (+1.53%)

USD21.88B 64.29 5.76
ARGX argenx NV ADR

+4.98 (+1.32%)

USD20.88B N/A -31.64
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AADI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -44.39% 47% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.39% 47% F 30% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.27B 63% D 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.03 49% F 41% F
Price / Cash Flow Ratio -11.93 84% B 79% C+
EV/EBITDA -1.05 55% F 67% D+
Management Effectiveness  
Return on Equity -221.95% 13% F 6% F
Return on Invested Capital -117.32% 17% F 9% F
Return on Assets -37.07% 27% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 7.06 34% F 20% F
Short Percent 4.79% 52% F 37% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.